Hola,
¿eres nuevo aquí?

Registrate y conecta tu empresa con financiación pública, partners y proyectos.

ONCOMAC

Financiado

Allogeneic Macrophages for Cancer Therapy

Macrophage cell therapy can become an attractive example of a cell therapy, with numerous potential applications, among them cancer therapy. While T-cell based therapies – so successful for the treatment of hematological malignanc... ver más

31/10/2023

TUD

150K€

Presupuesto del proyecto: 150K€

Líder del proyecto

TECHNISCHE UNIVERSITAET DRESDEN No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2023-10-31

Línea de financiación objetivo El proyecto se financió a través de la siguiente ayuda:

ERC-2022-POC1: ERC PROOF OF CONCEPT GRANTS1

I+D

Cerrada hace 3 años

0% 100% 100%

1 Participantes

TUD

150.00K€ | Lider

Proyectos interesantes

MiTE Developing the next generation of cis-targeting macrophage-T... 150K€ Cerrado

EicoMet Targeting eicosanoid metabolism to overcome tumor immunosupp... 150K€ Cerrado

CD20CARNAPT iTANK: a nuniversal technology to boost the efficacy of CAR... 4M€ Cerrado

FJC2019-041213-I Novel immunotherapy for cancer targeting macrophages 50K€ Cerrado

DETECTIVE DEmystifying Targets in Endothelial Cells for anti-Tumor Imm... 192K€ Cerrado

SynT Generation, validation and use of a synthetic reporter of CA... 150K€ Cerrado

Últimas noticias

29-11-2024: IDAE En las últimas 48 horas el Organismo IDAE ha otorgado 4 concesiones

29-11-2024: ECE En las últimas 48 horas el Organismo ECE ha otorgado 2 concesiones

29-11-2024: CMVAMADRID En las últimas 48 horas el Organismo CMVAMADRID ha otorgado 37 concesiones

Duración del proyecto: 18 meses Fecha Inicio: 2022-04-29
Fecha Fin: 2023-10-31

Líder del proyecto

TECHNISCHE UNIVERSITAET DRESDEN

TRL 4-5

Presupuesto del proyecto 150K€

Descripción del proyecto Macrophage cell therapy can become an attractive example of a cell therapy, with numerous potential applications, among them cancer therapy. While T-cell based therapies – so successful for the treatment of hematological malignancies! – have yet failed to demonstrate effectiveness in the treatment of solid tumors, macrophages are a key component of the tumor microenvironment (TME), and in principle they are capable of killing solid tumor cells. However, wildtype macrophages commonly respond to the TME by acquisition of a M2-like polarization state, in which state they rather support tumor growth and metastatic spread. This is a first problem for macrophage cell therapy against cancer. Besides, unlike T-cells, human macrophages cannot be expanded in cell culture, resulting in insufficient numbers of obtainable macrophages and thus limiting their utility for cell therapy. We have generated genetically engineered human macrophages, which have proliferative potential, are resistent to tumor-induced repolarization and thus demonstrate oncolytic activity. We want to translate these exciting findings into a cell-therapy against cancer. ONCOMAC relates to the preparation for and design of a preclinical proof-of-concept study for these genetically engineered human macrophages, so that we will have a sound basis for the translation of our genetically engineered macrophages into clinical trials. In particular, ONCOMAC will establish the numerous complex analytical procedures which are required by the European Medicine Agency's regulatory framework for First-in-human studies of an ATMP (Advanced Therapy Medicinal Product).

Conecta tu I+D

Entra hoy

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores